Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Neurology

Managing Symptoms: Standard of Care for HDL2

At a Glance

HDL2 has no cure or treatment proven to slow the disease, so care focuses on involuntary movements, stiffness, mood changes, and speech or swallowing problems. A neurologist-led team uses carefully monitored medicines, rehabilitation, and supportive therapies to protect safety and quality of life.

There is currently no cure or “disease-modifying” treatment for Huntington disease-like 2 (HDL2) [1]. Because HDL2 is so rare, there have not been large-scale clinical trials specifically for this condition [1][2]. Instead, medical experts extrapolate from the standard of care developed for Huntington’s Disease (HD) to manage symptoms and support quality of life, meaning many treatments may be off-label [3][4].

Treatment is symptomatic, meaning the goal is to reduce the impact of individual symptoms like involuntary movements, mood changes, and physical limitations [3].

Managing Movement Symptoms

The most visible symptoms of HDL2 are often movement-related. Depending on whether you have “extra” movements or “stiff” movements, your treatment plan will differ.

  • Chorea (Involuntary Movements): If “dance-like” twitching is interfering with your safety or daily tasks, doctors may prescribe VMAT2 inhibitors [5]. These medications, which include tetrabenazine, deutetrabenazine, and valbenazine, help reduce chorea by changing how chemicals move in the brain [6][7].
  • A Careful Balance: While effective, these drugs must be used cautiously and require specialist prescribing. Tetrabenazine and deutetrabenazine carry prominent product warnings regarding an increased risk of depression and suicidal thoughts. They can also cause severe side effects like sleepiness, akathisia (restlessness), or a “slowing down” of movement (parkinsonism) [8][9]. Contact your prescriber urgently for new or worsening depression or suicidal thoughts, and never stop or change the medicine without medical advice. Because many people with HDL2 naturally develop rigidity (stiffness) as the disease progresses, your doctor will monitor you closely to ensure the medication isn’t making that stiffness worse [3][10]. Regulatory approval for HD does not mean formal approval for HDL2.
  • Dystonia and Rigidity: For muscle cramping or stiffness, other medications or physical therapies may be used to help you stay mobile and comfortable [3].

Psychiatric and Emotional Care

Managing the “non-motor” symptoms of HDL2 is just as important as managing movement. These symptoms often require a combination of medication and expert counseling [11].

  • Mood and Anxiety: Medications like SSRIs (antidepressants) are commonly used to help with depression and anxiety [12].
  • Behavioral Changes: If you experience irritability, impulsivity, or psychosis (hallucinations or delusions), doctors may use antipsychotic medications [13]. These are selected based on your specific needs, as some can also help with chorea but may increase the risk of weight gain or stiffness [13][14].
  • Monitoring Insight: A common feature of these conditions is anosognosia—a “lack of insight” where the patient may not realize how much their mood or behavior has changed [15][16]. For this reason, with your consent, your care team may use collateral information from your family and caregivers to complement your own report, tracking how well treatments are working without erasing your preferences [17].

Your Multidisciplinary Care Team

Because HDL2 affects many parts of your life, you need a team of specialists who communicate with each other. This is called a multidisciplinary care team [11].

  • Neurologist: Usually the “lead” doctor who monitors your movement and manages medications [11].
  • Psychiatrist, Psychologist, or Neuropsychologist: A psychiatrist manages psychiatric diagnoses and medications, a psychologist or counselor provides talk therapy, and a neuropsychologist evaluates cognition to guide rehabilitation [18]. It is important to individualize this team based on your specific needs.
  • Physical and Occupational Therapists (PT/OT): Work to improve your balance, strength, and safety at home [19]. Exercise is an individualized, safety-screened intervention supported by general neurorehabilitation evidence, which can help support overall well-being [19][20].
  • Speech-Language Pathologist (SLP): Crucial for helping with dysarthria (speech clarity) and performing swallowing evaluations to prevent choking or lung infections (aspiration) [21][22].
  • Dietician/Nutritionist: Helps you maintain a healthy weight, which can be difficult as movements burn extra calories or swallowing becomes harder [23].

Timing and Proactive Care

The best time to build this team is as soon as possible after diagnosis. Early involvement from PT, OT, and SLP allows them to create a “baseline” of your abilities, making it easier to notice and address small changes before they become major problems [19][21].

While you may not need every specialist right away, knowing who they are and how to reach them provides a safety net for you and your family as you navigate the road ahead [11].

Common questions in this guide

Is there a cure or disease-slowing treatment for HDL2?
There is currently no cure or treatment proven to slow HDL2. Because HDL2 is very rare and lacks large clinical trials, clinicians generally adapt symptom-management approaches used for Huntington disease, and some medicines may be used outside their formal HDL2 approval.
What medicines can reduce involuntary movements in HDL2?
Doctors may consider VMAT2 inhibitors such as tetrabenazine, deutetrabenazine, or valbenazine when involuntary movements interfere with safety or daily activities. These medicines require specialist prescribing and monitoring because they can cause sleepiness, restlessness, slowed or stiff movement, and serious mood changes.
What warning signs should I watch for with VMAT2 inhibitors?
Tetrabenazine and deutetrabenazine carry warnings about depression and suicidal thoughts. Contact the prescriber urgently for new or worsening mood symptoms, and report severe sleepiness, restlessness, or worsening stiffness; do not stop or change these medicines without medical advice.
How are depression, anxiety, or behavior changes treated in HDL2?
Selective serotonin reuptake inhibitors may be used for depression and anxiety, while antipsychotic medicines may help with irritability, impulsivity, or psychosis. Counseling and regular review by a mental-health specialist can be combined with medicine, and family or caregiver observations may help the team assess changes when the patient agrees.
Which specialists are usually involved in HDL2 care?
A neurologist often coordinates care, with psychiatry or psychology, neuropsychology, physical and occupational therapy, speech-language pathology, and nutrition support added according to the person's needs. Building the team early can establish a baseline and help identify changes in movement, thinking, communication, swallowing, or safety.
How can therapy help with speech, swallowing, movement, and daily safety?
Physical and occupational therapists can work on balance, strength, mobility, and safety at home. A speech-language pathologist can address unclear speech and evaluate swallowing to reduce choking and aspiration, while a dietitian can help maintain weight when movements or swallowing make eating difficult.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Since treatments are extrapolated from HD guidelines, how do we evaluate if an off-label medication is the right choice for my specific symptoms?
  2. 2.If we consider a VMAT2 inhibitor for my chorea, what is our plan to monitor for severe side effects like depression, suicidal thoughts, or worsening parkinsonism?
  3. 3.Which members of the multidisciplinary team (like a physical therapist or speech pathologist) should I see first, and do they have experience with Huntington-like disorders?
  4. 4.How often should we review my psychiatric medications to ensure they aren't negatively interacting with my movement treatments?
  5. 5.Are there specific mood or behavioral changes—like apathy or irritability—that you recommend we track using formal screening scales during our visits?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Current knowledge of Huntington's disease-like 2 genetic testing, clinical presentation, and patient experiences: A systematic review.

    Hoffmann K, White S, Sexton A

    Journal of Huntington's disease 2026; (15(3)):293-316 doi:10.1177/18796397251411109.

    PMID: 41564273
  2. 2

    Comparative analysis of neurofilament light chain in Huntington's disease like 2 and Huntington's disease.

    Anderson DG, Ferreira-Correia A, Rodrigues FB, et al.

    Journal of Huntington's disease 2025; (14(1)):103-108 doi:10.1177/18796397241300141.

    PMID: 39973395
  3. 3

    Comparison of the Huntington's Disease like 2 and Huntington's Disease Clinical Phenotypes.

    Anderson DG, Ferreira-Correia A, Rodrigues FB, et al.

    Movement disorders clinical practice 2019; (6(4)):302-311 doi:10.1002/mdc3.12742.

    PMID: 31061838
  4. 4

    International Guidelines for the Treatment of Huntington's Disease.

    Bachoud-Lévi AC, Ferreira J, Massart R, et al.

    Frontiers in neurology 2019; (10()):710 doi:10.3389/fneur.2019.00710.

    PMID: 31333565
  5. 5

    Safety and efficacy of VMAT2 inhibitors in Huntington Disease: A systematic review.

    Baghaei A, Dehnavi AZ, Hashempour Z, et al.

    Parkinsonism & related disorders 2026; (145()):108209 doi:10.1016/j.parkreldis.2026.108209.

    PMID: 41651710
  6. 6

    Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.

    , Frank S, Testa CM, et al.

    JAMA 2016; (316(1)):40-50 doi:10.1001/jama.2016.8655.

    PMID: 27380342
  7. 7

    Huntington Disease and Chorea.

    Moore KPL

    Continuum (Minneapolis, Minn.) 2025; (31(4)):1066-1092 doi:10.1212/cont.0000000000001597.

    PMID: 40748130
  8. 8

    Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease.

    Claassen DO, Carroll B, De Boer LM, et al.

    Journal of clinical movement disorders 2017; (4()):3 doi:10.1186/s40734-017-0051-5.

    PMID: 28265459
  9. 9

    The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study.

    Frank S, Testa C, Edmondson MC, et al.

    CNS drugs 2022; (36(11)):1207-1216 doi:10.1007/s40263-022-00956-8.

    PMID: 36242718
  10. 10

    Atypical Presentations of Huntington Disease-like 2 in South African Individuals.

    Narotam-Jeena H, Guttman M, van Hillegondsberg L, et al.

    Movement disorders clinical practice 2024; (11(7)):850-854 doi:10.1002/mdc3.14052.

    PMID: 38725192
  11. 11

    What we don't need to prove but need to do in multidisciplinary treatment and care in Huntington's disease: a position paper.

    Mühlbӓck A, van Walsem M, Nance M, et al.

    Orphanet journal of rare diseases 2023; (18(1)):19 doi:10.1186/s13023-023-02622-8.

    PMID: 36717864
  12. 12

    Different depression: motivational anhedonia governs antidepressant efficacy in Huntington's disease.

    McLauchlan DJ, Lancaster T, Craufurd D, et al.

    Brain communications 2022; (4(6)):fcac278 doi:10.1093/braincomms/fcac278.

    PMID: 36440100
  13. 13

    Comparison of tetrabenazine, tiapride and olanzapine in Huntington's disease: a one-year French randomized multicenter study (Neuro-HD).

    Youssov K, Audureau E, Pariente J, et al.

    Parkinsonism & related disorders 2025; (140()):108017 doi:10.1016/j.parkreldis.2025.108017.

    PMID: 41014964
  14. 14

    Nonmotor Symptoms in Huntington Disease.

    Cardoso F

    International review of neurobiology 2017; (134()):1397-1408 doi:10.1016/bs.irn.2017.05.004.

    PMID: 28805577
  15. 15

    Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations.

    Mestre TA, van Duijn E, Davis AM, et al.

    Movement disorders : official journal of the Movement Disorder Society 2016; (31(10)):1466-1478 doi:10.1002/mds.26675.

    PMID: 27296904
  16. 16

    Anosognosia Is Associated With Greater Caregiver Burden and Poorer Executive Function in Huntington Disease.

    Wibawa P, Zombor R, Dragovic M, et al.

    Journal of geriatric psychiatry and neurology 2020; (33(1)):52-58 doi:10.1177/0891988719856697.

    PMID: 31213121
  17. 17

    The Impact of Anosognosia on Clinical and Patient-Reported Assessments of Psychiatric Symptoms in Huntington's Disease.

    Isaacs D, Gibson JS, Stovall J, Claassen DO

    Journal of Huntington's disease 2020; (9(3)):291-302 doi:10.3233/JHD-200410.

    PMID: 32925080
  18. 18

    Huntington Study Group's Neuropsychology Working Group: Implementing Non-Motor Diagnostic Criteria.

    Considine CM, Rossetti MA, Del Bene VA, et al.

    Movement disorders clinical practice 2023; (10(12)):1714-1724 doi:10.1002/mdc3.13910.

    PMID: 38094638
  19. 19

    Clinical recommendations to guide physical therapy practice for Huntington disease.

    Quinn L, Kegelmeyer D, Kloos A, et al.

    Neurology 2020; (94(5)):217-228 doi:10.1212/WNL.0000000000008887.

    PMID: 31907286
  20. 20

    Clinical Decision Trees to Guide Physical Therapy Management of Persons with Huntington's Disease.

    Fritz NE, Kegelmeyer DA, Rao AK, et al.

    Journal of Huntington's disease 2022; (11(4)):435-453 doi:10.3233/JHD-220549.

    PMID: 36155527
  21. 21

    Management of dysphagia in Huntington's disease: a descriptive review.

    Pizzorni N, Pirola F, Ciammola A, Schindler A

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2020; (41(6)):1405-1417 doi:10.1007/s10072-020-04265-0.

    PMID: 31989345
  22. 22

    Clinical predictors and neural correlates for compromised swallowing safety in Huntington disease.

    Schumann-Werner B, Dogan I, Mirzazade S, et al.

    European journal of neurology 2021; (28(9)):2855-2862 doi:10.1111/ene.14953.

    PMID: 34077591
  23. 23

    Relationship between Nutritional Status and the Severity of Huntington’s Disease. A Spanish Multicenter Dietary Intake Study.

    Cubo E, Rivadeneyra J, Armesto D, et al.

    Journal of Huntington's disease 2015; (4(1)):78-85.

    PMID: 26333259

This page is for informational purposes only and does not constitute medical advice. Treatment choices for HDL2, including medicines used outside their formal approval for this condition, should be made with your neurologist and multidisciplinary care team.

Get notified when new evidence is published on Huntington disease-like 2.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.